Skip to main content
Premium Trial:

Request an Annual Quote

Zymark and Bayer Collaborate on Cell-Based Transcription Assay

NEW YORK, Jan 2 – Bayer and Zymark of Hopkinton, Mass. have developed a cell-based assay kit that allows laboratories to design assays for any gene target or type of cell and run an automated assay, the companies announced Tuesday.

The package includes Bayer’s QuantiGene assays, HV kit, and ProbeDesigner software, as well as Zymark’s Staccato workstation.

The QuantiGene assay and HV kit is designed to measure the expression of cellular mRNA without the sample preparation phase. The ProbeDesigner software allows a researcher to design specific probes for mRNA targets.

According to Bayer, the Staccato workstation can complete 10,000 assays in 24 hours, and can be adapted easily for assays on different gene targets.

" Through the collaboration with Zymark, our companies are able to provide an assay solutions package employing innovative mRNA quantitation technology and the latest in high-throughput automation,” said Stephen Chamberlain, senior marketing manager for QuantiGene technologies at Bayer. “We are helping laboratories streamline their lead identification and validation processes by providing the means to obtain data of high value, eliminating the time required to develop the assay, and shortening the overall run time.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.